Sequelae of Pelvic Inflammatory Disease
Conditions
Interventions
Experimental Group:Fuyan San Chinese Herbal Pack (Standard Dosage)
Control Group:Fuyan San Chinese herbal medicine package (low dose/placebo)
Sponsors
Guizhou University of Traditional Chinese Medicine First Affiliated Hospital
Eligibility
Sex/Gender
Female
Age
20 Years to 45 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria (1) Patients who meet the diagnostic criteria for SPID in Western medicine. (2) Patients who meet the diagnostic criteria for the damp-heat and blood stasis pattern. (3) Patients with a pain score NRS =4. (4) Patients aged 20-45 years with a history of sexual activity. (5) Patients with regular menstrual cycles of 28-35 days, and each menstrual period lasting 3-7 days. (6) Patients who voluntarily participate in this study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: Exclusion Criteria (1) Participants who do not meet the SPID diagnostic criteria; (2) Women in pregnancy, lactation, with fertility intentions, or with menstrual cycle disorders; (3) Patients with severe cardiovascular, hepatic, renal, or hematological diseases; (4) Patients with confirmed gynecological tumors (including uterine fibroids with a single maximum diameter >3cm), acute cervicitis, adenomyosis, endometriosis, pelvic congestion syndrome, or tuberculous pelvic inflammation; (5) Patients with pelvic masses >6cm; (6) Patients with concurrent vulvovaginal candidiasis, bacterial vaginosis, or trichomoniasis; (7) Patients with acute pelvic inflammatory disease; (8) Patients with a history of allergy or hypersensitivity to the drugs used in this trial; (9) Patients with local skin erythema, infection, ulceration, or contagious dermatoses; (10) Patients with mental or cognitive disorders, or intellectual disabilities that prevent cooperation; (11) Patients who have received similar drug therapy in the past 2 months, which may affect the interpretation of trial results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Chronic pelvic pain disappearance rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Chronic pelvic pain disappearance rate;Local Sign Scoring;TCM syndrome score;B-mode ultrasound; | — |
Countries
China
Contacts
Public ContactZhai Tingting
Guizhou University of Traditional Chinese Medicine First Affiliated Hospital
Outcome results
None listed